Treating moderate to severe psoriasis - Best use of biologics

Maeve Lynch; Brian Kirby; Richard B. Warren

doi:10.1586/1744666X.2014.873701

Treating moderate to severe psoriasis - Best use of biologics

Maeve Lynch, Brian Kirby, Richard B. Warren

Research output: Contribution to journal › Article › peer-review

Abstract

This review focuses on the efficacy, safety and best use of biologic agents in moderate-to-severe psoriasis. Recommendations from two recent guidelines are summarised. The NICE Guidelines 2012 provide recommendations on best practice for prescribing biologics. The German S3 Guidelines are based on a systematic review of published studies and report the efficacy of biologics and guidelines for treatment. Data on the safety of biologics are available for up to 5 years in psoriasis and are on the whole reassuring. Registry data is evolving and will provide data on safety to help inform long-term monitoring of patients with psoriasis on biologics agents. New anti-interleukin-17 (IL17) and anti-IL17RA biologics are in Phase 3 clinical trials and may prove to be more effective than existing biologics. © 2014 Informa UK Ltd.

Original language	English
Pages (from-to)	269-279
Number of pages	10
Journal	Expert review of clinical immunology
Volume	10
Issue number	2
DOIs	https://doi.org/10.1586/1744666X.2014.873701
Publication status	Published - Feb 2014

Keywords

biologics
efficacy
psoriasis
registries
safety

Access to Document

10.1586/1744666X.2014.873701

Cite this

@article{4313862e576e4cb5b65df9f9e4d780ff,

title = "Treating moderate to severe psoriasis - Best use of biologics",

abstract = "This review focuses on the efficacy, safety and best use of biologic agents in moderate-to-severe psoriasis. Recommendations from two recent guidelines are summarised. The NICE Guidelines 2012 provide recommendations on best practice for prescribing biologics. The German S3 Guidelines are based on a systematic review of published studies and report the efficacy of biologics and guidelines for treatment. Data on the safety of biologics are available for up to 5 years in psoriasis and are on the whole reassuring. Registry data is evolving and will provide data on safety to help inform long-term monitoring of patients with psoriasis on biologics agents. New anti-interleukin-17 (IL17) and anti-IL17RA biologics are in Phase 3 clinical trials and may prove to be more effective than existing biologics. {\textcopyright} 2014 Informa UK Ltd.",

keywords = "biologics, efficacy, psoriasis, registries, safety",

author = "Maeve Lynch and Brian Kirby and Warren, {Richard B.}",

year = "2014",

month = feb,

doi = "10.1586/1744666X.2014.873701",

language = "English",

volume = "10",

pages = "269--279",

journal = "Expert review of clinical immunology",

issn = "1744-8409",

publisher = "Expert Reviews Ltd",

number = "2",

}

TY - JOUR

T1 - Treating moderate to severe psoriasis - Best use of biologics

AU - Lynch, Maeve

AU - Kirby, Brian

AU - Warren, Richard B.

PY - 2014/2

Y1 - 2014/2

N2 - This review focuses on the efficacy, safety and best use of biologic agents in moderate-to-severe psoriasis. Recommendations from two recent guidelines are summarised. The NICE Guidelines 2012 provide recommendations on best practice for prescribing biologics. The German S3 Guidelines are based on a systematic review of published studies and report the efficacy of biologics and guidelines for treatment. Data on the safety of biologics are available for up to 5 years in psoriasis and are on the whole reassuring. Registry data is evolving and will provide data on safety to help inform long-term monitoring of patients with psoriasis on biologics agents. New anti-interleukin-17 (IL17) and anti-IL17RA biologics are in Phase 3 clinical trials and may prove to be more effective than existing biologics. © 2014 Informa UK Ltd.

AB - This review focuses on the efficacy, safety and best use of biologic agents in moderate-to-severe psoriasis. Recommendations from two recent guidelines are summarised. The NICE Guidelines 2012 provide recommendations on best practice for prescribing biologics. The German S3 Guidelines are based on a systematic review of published studies and report the efficacy of biologics and guidelines for treatment. Data on the safety of biologics are available for up to 5 years in psoriasis and are on the whole reassuring. Registry data is evolving and will provide data on safety to help inform long-term monitoring of patients with psoriasis on biologics agents. New anti-interleukin-17 (IL17) and anti-IL17RA biologics are in Phase 3 clinical trials and may prove to be more effective than existing biologics. © 2014 Informa UK Ltd.

KW - biologics

KW - efficacy

KW - psoriasis

KW - registries

KW - safety

U2 - 10.1586/1744666X.2014.873701

DO - 10.1586/1744666X.2014.873701

M3 - Article

C2 - 24372444

SN - 1744-8409

VL - 10

SP - 269

EP - 279

JO - Expert review of clinical immunology

JF - Expert review of clinical immunology

IS - 2

ER -

Treating moderate to severe psoriasis - Best use of biologics

Abstract

Keywords

Access to Document

Fingerprint

Cite this